Navigation Links
Astellas Signs Distribution Agreement With Tecnofarma For Enzalutamide In Latin America
Date:6/5/2013

NORTHBROOK, Ill., June 5, 2013 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that the company has entered into a distribution agreement with Tecnofarma International Ltd. to distribute enzalutamide (XTANDI® in the U.S.)  in Latin America, excluding Brazil, upon regulatory approvals in the various countries. Financial terms of the agreements were not disclosed.

"We are pleased to initiate a distribution arrangement for enzalutamide with Tecnofarma, which represents an important milestone to further expand our oncology business in Latin America," said Martin Mercer , Vice President of Latin America. "Tecnofarma, with whom Astellas already has a relationship through our Mycamine® distribution agreement in Latin America, has a strong Latin American sales and marketing oncology organization, which is why they are an ideal partner to help build the Astellas oncology pipeline with enzalutamide."

Jorge Ramos , CEO Latin America for Tecnofarma: "We want to thank Astellas for trusting us with the distribution rights of this important product. It is an extremely valuable new option for patients in this region."

About Enzalutamide
Enzalutamide (XTANDI® in the U.S.) is an oral, once-daily androgen receptor inhibitor. XTANDI was approved by the U.S. Food and Drug Administration on August 31, 2012 for the treatment of metastatic castration resistant prostate cancer for patients who have previously received docetaxel (chemotherapy). On May 30, 2013, Health Canada approved XTANDI (enzalutamide) capsules for the treatment of patients with metastatic castration-resistant
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
2. Astellas and Fujita Health University Discover Neuronal Maturation Deficits in Patients Suffering from Schizophrenia and Bipolar Disorder
3. Astellas to Close Urogenix, North Carolina-based Urology Research Facility
4. Personal Connections Drive Employee Participation For Changing Tomorrow Day at Astellas
5. Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsules
6. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
7. Astellas Highlights Progress to Advance Care of Patients with Genitourinary Cancers at ASCO-GU Annual Meeting
8. Astellas to Drive PGA TOURs New Womens Initiative
9. PGA TOUR Celebrates Official Launch of the Astellas Presents Executive Womens Day Program
10. Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
11. Astellas Pharma Inc.: New Hire Reinforces Global Compliance Structure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NEW YORK , January 15, 2014 ... BreedIT Ltd., the exclusive worldwide distributor of highly sophisticated ... that on January 7, 2014, the Company,s board of ... Ben-Zion Weiner as its new member of the ...
(Date:1/15/2014)... Inc. (Nasdaq: ECTE ) ("Echo"), a medical ... non-invasive, wireless continuous glucose monitoring system, today announced that ... CEO of Echo Therapeutics, will present at "TEN", Noble ... Mr. Doman will make a corporate presentation to ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... 5, 2011 Nektar Therapeutics (Nasdaq: NKTR ... patients in a Phase 2 clinical study evaluating single-agent ... of 33 women in the study with prior Doxil® ... response rate using either RECIST 1.0 criteria (response by ...
... CHICAGO, June 4, 2011 Genomic Health, Inc. (Nasdaq: ... studies being presented at the American Society of Clinical ... study confirming the performance of the Onco type ... predictor of recurrence risk in stage II colon cancer. ...
Cached Medicine Technology:NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 2NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 3NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 4NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 5NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 6NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 7NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 8Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 2Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 3Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 4Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 5Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 6Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 7Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 8Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 9
(Date:7/11/2014)... IN (PRWEB) July 11, 2014 New Albany ... be startled with the idea of paying $20,000 for new teeth. ... makes it worth it for many patients,” Dr. Receveur said. , ... foods they love, or have a lifetime of embarrassment over their ... – they’re paying for a better, more enjoyable life. , Still, ...
(Date:7/10/2014)... CO (PRWEB) July 11, 2014 Karen ... Cowart, President and CEO of Planned Parenthood of the ... fact Senator Mark Udall and Representative Diana DeGette were ... Supreme Court’s Hobby Lobby decision and keeping bosses out ... PPRM representatives listened to the president today in Denver ...
(Date:7/10/2014)... 10, 2014 Ticketability.com has a wide array ... Paul McCartney tickets for San Diego are being added to ... since 1976, and the newly added September 28 show is ... Click Here to view the selection of discounted ... Park will become available to the general public on July ...
(Date:7/10/2014)... York City, NY (PRWEB) July 10, 2014 ... the life sciences industry, has launched a new website. ... responsiveness, as well as increased access to the firm’s ... new cbpartners.com provides an ideal platform to showcase our ... health access issues,” says CBPartners’ Chief Executive Officer, Cyrus ...
(Date:7/10/2014)... 10, 2014 Ivalua, the global ... of the 4th “Trending in Procurement” report on ... , Every day multinational corporations process thousands of ... etc. To meet this challenge, more and more ... can be defined as a suite of integrated ...
Breaking Medicine News(10 mins):Health News:Louisville Dental Expert Offers 5 Tips for Deciding Whether Cost or Value of Dental Implants are More Important 2Health News:Louisville Dental Expert Offers 5 Tips for Deciding Whether Cost or Value of Dental Implants are More Important 3Health News:Louisville Dental Expert Offers 5 Tips for Deciding Whether Cost or Value of Dental Implants are More Important 4Health News:Naral Pro-Choice Colorado & Planned Parenthood Of The Rocky Mountains Statement On Udall & Degette Staying In Dc To Introduce Legislation 2Health News:Paul McCartney Tickets for San Diego: Ticketability.com Announces Discounted Tickets for McCartney’s Tour Stop at Petco Park on September 28 2Health News:CBPartners Announces New Website 2Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 2Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 3
... new study show that Aldara (imiquimod) Cream 5 percent, which ... process of premature aging and improve the complexion of the ... improvement in fine lines, wrinkles, dyspigmentations and texture. ... facility presented these findings at the 64th Annual Meeting of ...
... lifting weights, a new study shows. Weight lifting at least ... your waist. In addition, it can ensure a healthy heart ... among nearly 164 obese or overweight women. The study participants ... The experimental group members were required to undertake strength training ...
... When children turn into adults, some genes involved in controlling ... a study of more than 500 pairs of twins. //,Black ... showed that changes in gene expression between ages 14 and ... pressure variation that occurred by age 18. This was told ...
... apnea is a disorder that can contribute to the development ... to 20 million Americans// have obstructive sleep apnea, but most ... risk factor is obesity. Men are twice as likely as ... Sleep Medicine (AASM) said that a treatment called continuous positive ...
... to 12 million suffer from winter depression, of which ... 35 years of age.// ,Current research indicates ... that may cause symptoms such as loss of energy, ... and sleepiness. Individuals affected by "winter depression" who go ...
... group of friends and family frustrated with dieting and weight ... them to lose more than 75 lbs. over a 4 ... to lose over 75 lbs, exercise more than 25 miles, ... original body weight., ,The competition began with Jen sending ...
Cached Medicine News:Health News:Gene alteration observed in children turning into adults 2Health News:'Winter Blues' Treated by Breakthrough Lighting Technology 2
... for catheter or instrument introduction. The ... be peeled away and removed. The ... instrument to be introduced should be ... the sheath. Supplied sterile in peel-open ...
Used for stenting the urethra after hypospadias or epispadias repair and to provide post-operative drainage of the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
... Used to provide ... or epispadias repair. The ... to partially close during ... urethra while maintaining urethral ...
... temporary internal drainage from ... the bladder. Supplied sterile ... for one-time use. CAUTION: ... C-Flex® and Sof-Flex® stents ...
Medicine Products: